Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis
IntroductionDirect antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilapre...
Saved in:
Main Authors: | Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Gastroenterology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fgstr.2025.1511150/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
by: Jiayi Wang, et al.
Published: (2024-12-01) -
Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study
by: Guilherme Thomé de Carvalho, et al.
Published: (2025-02-01) -
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01) -
Direct-Acting Antivirals in Hepatitis C Treatment for Renal Impairment: Liver Safety Concerns and Effectiveness in Peritoneal Dialysis
by: Hsuan-Yu Hung, et al.
Published: (2024-12-01) -
Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
by: L. Tang, et al.
Published: (2018-01-01)